Literature DB >> 22691695

Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease.

Jeanne M Palmer1, Stephanie J Lee, Xiaoyu Chai, Barry E Storer, Mary E D Flowers, Kirk R Schultz, Yoshihiro Inamoto, Corey Cutler, Joseph Pidala, Mukta Arora, David A Jacobsohn, Paul A Carpenter, Steven Z Pavletic, Paul J Martin.   

Abstract

In 2005, a National Institutes of Health consensus conference was held to refine methods for research in patients with chronic graft-versus-host disease, including proposed objective response measures and a provisional algorithm for calculating organ-specific and overall response. In this study, we used weighted kappa statistics to evaluate the level of agreement between clinician response ratings and calculated response categories in patients with chronic graft-versus-host disease. The study included 290 patients who had paired enrollment and follow-up visits. Based on a set of objective measures, 37% of the patients had an overall complete or partial response, whereas clinicians reported an overall complete or partial response rate of 71% (slight to fair agreement, weighted kappa 0.20). Agreement rates between calculated organ-specific responses and clinician-reported changes in skin, mouth, and eyes were fair to moderate (weighted kappa, 0.28-0.54). We conclude that for both overall and organ-specific comparisons, clinician response ratings did not agree well with calculated response categories. Possible reasons for this discrepancy include a high clinical sensitivity for detecting response, a clinical predisposition to recognize selective improvements as overall response, the large change in objective measures proposed to define response, and the high incidence of progressive disease based on new manifestations. Conclusions from prior literature reporting high overall response rates based on clinician judgment would not be supported if the provisional algorithm had been applied to calculate response. Our analysis also highlights the need to define an overall response measure that incorporates both patient-reported and objective measures and accurately reflects the outcome in patients with a mixed response in which one organ or site improves, whereas another shows new involvement.
Copyright © 2012 American Society for Blood and Marrow Transplantation. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22691695      PMCID: PMC3448865          DOI: 10.1016/j.bbmt.2012.05.005

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  20 in total

1.  Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease.

Authors:  Alessandro Busca; Franco Locatelli; Filippo Marmont; Ernesta Audisio; Michele Falda
Journal:  Haematologica       Date:  2003-07       Impact factor: 9.941

2.  Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD.

Authors:  Daniel R Couriel; Chitra Hosing; Rima Saliba; Elizabeth J Shpall; Paolo Anderlini; Beverly Rhodes; Veronica Smith; Issa Khouri; Sergio Giralt; Marcos de Lima; Yvonne Hsu; Shubhra Ghosh; Joyce Neumann; Borje Andersson; Muzzafar Qazilbash; Sharon Hymes; Stella Kim; Richard Champlin; Michele Donato
Journal:  Blood       Date:  2005-12-20       Impact factor: 22.113

3.  Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease.

Authors:  D R Couriel; R Saliba; M P Escalón; Y Hsu; S Ghosh; C Ippoliti; K Hicks; M Donato; S Giralt; I F Khouri; C Hosing; M J de Lima; B Andersson; J Neumann; R Champlin
Journal:  Br J Haematol       Date:  2005-08       Impact factor: 6.998

4.  Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease.

Authors:  M Arora; J E Wagner; S M Davies; B R Blazar; T Defor; H Enright; W J Miller; D F Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2001       Impact factor: 5.742

5.  Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.

Authors:  Steven Z Pavletic; Paul Martin; Stephanie J Lee; Sandra Mitchell; David Jacobsohn; Edward W Cowen; Maria L Turner; Gorgun Akpek; Andrew Gilman; George McDonald; Mark Schubert; Ann Berger; Peter Bross; Jason W Chien; Daniel Couriel; J P Dunn; Jane Fall-Dickson; Ann Farrell; Mary E D Flowers; Hildegard Greinix; Steven Hirschfeld; Lynn Gerber; Stella Kim; Robert Knobler; Peter A Lachenbruch; Frederick W Miller; Barbara Mittleman; Esperanza Papadopoulos; Susan K Parsons; Donna Przepiorka; Michael Robinson; Michael Ward; Bryce Reeve; Lisa G Rider; Howard Shulman; Kirk R Schultz; Daniel Weisdorf; Georgia B Vogelsang
Journal:  Biol Blood Marrow Transplant       Date:  2006-03       Impact factor: 5.742

6.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

7.  Validation of measurement scales in ocular graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Xiaoyu Chai; Brenda F Kurland; Corey Cutler; Mary E D Flowers; Jeanne M Palmer; Paul A Carpenter; Mary J Heffernan; David Jacobsohn; Madan H Jagasia; Joseph Pidala; Nandita Khera; Georgia B Vogelsang; Daniel Weisdorf; Paul J Martin; Steven Z Pavletic; Stephanie J Lee
Journal:  Ophthalmology       Date:  2011-12-06       Impact factor: 12.079

8.  Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease.

Authors:  David A Jacobsohn; Allen R Chen; Marianna Zahurak; Steven Piantadosi; Viki Anders; Javier Bolaños-Meade; Meghan Higman; Jeffrey Margolis; Michele Kaup; Georgia B Vogelsang
Journal:  J Clin Oncol       Date:  2007-09-20       Impact factor: 44.544

9.  Rituximab for steroid-refractory chronic graft-versus-host disease.

Authors:  Corey Cutler; David Miklos; Haesook T Kim; Nathaniel Treister; Sook-Bin Woo; Don Bienfang; Lloyd B Klickstein; Jesse Levin; Katherine Miller; Carol Reynolds; Rebecca Macdonell; Mildred Pasek; Stephanie J Lee; Vincent Ho; Robert Soiffer; Joseph H Antin; Jerome Ritz; Edwin Alyea
Journal:  Blood       Date:  2006-03-21       Impact factor: 22.113

10.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

View more
  13 in total

Review 1.  How we treat chronic graft-versus-host disease.

Authors:  Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2014-11-14       Impact factor: 22.113

2.  A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.

Authors:  Sally Arai; Joseph Pidala; Iskra Pusic; Xiaoyu Chai; Samantha Jaglowski; Nandita Khera; Jeanne Palmer; George L Chen; Madan H Jagasia; Sebastian A Mayer; William A Wood; Michael Green; Teresa S Hyun; Yoshihiro Inamoto; Barry E Storer; David B Miklos; Howard M Shulman; Paul J Martin; Stefanie Sarantopoulos; Stephanie J Lee; Mary E D Flowers
Journal:  Clin Cancer Res       Date:  2015-09-16       Impact factor: 12.531

3.  Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease.

Authors:  Paul J Martin; Barry E Storer; Jeanne Palmer; Madan H Jagasia; George L Chen; Raewyn Broady; Mukta Arora; Joseph A Pidala; Betty K Hamilton; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2019-05-11       Impact factor: 5.742

Review 4.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report.

Authors:  Paul J Martin; Stephanie J Lee; Donna Przepiorka; Mary M Horowitz; John Koreth; Georgia B Vogelsang; Irwin Walker; Paul A Carpenter; Linda M Griffith; Gorgun Akpek; Mohamad Mohty; Daniel Wolff; Steven Z Pavletic; Corey S Cutler
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-15       Impact factor: 5.742

5.  Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Barry E Storer; Stephanie J Lee; Paul A Carpenter; Brenda M Sandmaier; Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

6.  Plasma CXCL9 elevations correlate with chronic GVHD diagnosis.

Authors:  Carrie L Kitko; John E Levine; Barry E Storer; Xiaoyu Chai; David A Fox; Thomas M Braun; Daniel R Couriel; Paul J Martin; Mary E Flowers; John A Hansen; Lawrence Chang; Megan Conlon; Bryan J Fiema; Rachel Morgan; Prae Pongtornpipat; Kelly Lamiman; James L M Ferrara; Stephanie J Lee; Sophie Paczesny
Journal:  Blood       Date:  2013-12-20       Impact factor: 22.113

7.  Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium.

Authors:  N Treister; X Chai; B Kurland; S Pavletic; D Weisdorf; J Pidala; J Palmer; P Martin; Y Inamoto; M Arora; M Flowers; D Jacobsohn; M Jagasia; S Arai; S J Lee; C Cutler
Journal:  Bone Marrow Transplant       Date:  2013-01-28       Impact factor: 5.483

Review 8.  Current issues in chronic graft-versus-host disease.

Authors:  Gérard Socié; Jerome Ritz
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

9.  Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease.

Authors:  Jeanne Palmer; Xiaoyu Chai; Joseph Pidala; Yoshihiro Inamoto; Paul J Martin; Barry Storer; Iskra Pusic; Mary E D Flowers; Mukta Arora; Steven Z Pavletic; Stephanie J Lee
Journal:  Blood       Date:  2015-11-02       Impact factor: 22.113

Review 10.  Graft-versus-host disease: state of the science.

Authors:  Amin M Alousi; Javier Bolaños-Meade; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-27       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.